PolyPid unveils expanded pipeline strategy with new diabetic foot infection candidate
PYPD•PolyPid introduced PD01B, a Kynatrix-based product candidate for diabetic foot infections; a pre-IND meeting and first-in-human study are expected in the second half of 2027. The D-PLEX₁₀₀ PDUFA goal date is November 28, 2026.
1. Pipeline and timeline
PolyPid introduced PD01B, a new Kynatrix-based product candidate for diabetic foot infections. The company expects a pre-IND meeting and first-in-human study in the second half of 2027; the D-PLEX₁₀₀ PDUFA goal date is November 28, 2026.
